Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer

Mi Deng, Heyu Chen, Xiaoye Liu, Ryan Huang, Yubo He, Byounggyu Yoo, Jingjing Xie, Samuel John, Ningyan Zhang, Zhiqiang An, Cheng Cheng Zhang

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Inhibitory leukocyte immunoglobulin-like receptors (LILRBs 1–5) transduce signals via intracellular immunoreceptor tyrosine-based inhibitory motifs that recruit phosphatases to negatively regulate immune activation. The activation of LILRB signaling in immune cells may contribute to immune evasion. In addition, the expression and signaling of LILRBs in cancer cells especially in certain hematologic malignant cells directly support cancer development. Certain LILRBs thus have dual roles in cancer biology—as immune checkpoint molecules and tumor-supporting factors. Here, we review the expression, ligands, signaling, and functions of LILRBs, as well as therapeutic development targeting them. LILRBs may represent attractive targets for cancer treatment, and antagonizing LILRB signaling may prove to be effective anti-cancer strategies.

Original languageEnglish (US)
Pages (from-to)16-33
Number of pages18
JournalAntibody Therapeutics
Issue number1
StatePublished - Jan 1 2021


  • Cancer
  • Immune inhibitory receptor
  • Immunoglobulin-like domain
  • Immunoreceptor tyrosine-based inhibitory motif
  • ITIM
  • Leukocyte immunoglobulin-like receptor subfamily B
  • Signal transduction

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer'. Together they form a unique fingerprint.

Cite this